Tildrakizumab is a high-affinity, humanized IgG1κ monoclonal antibody targeting the p19 subunit of IL-23, which is a key regulatory cytokine in psoriasis and stimulates the differentiation, proliferation and survival of T helper 17 cells. Here, IL23A is linked to psoriasis.